Inactive Instrument

Alopexx, Inc.

ALPX

US02052J1016

Biotechnology & Medical Research

Alopexx, Inc. has filed an IPO in the amount of $18.328125 million.

March 04, 2022 at 12:00 am EST

Alopexx, Inc. has filed an IPO in the amount of $18.328125 million.

Security Name: common Stock
Security Type: Common Stock

Latest news about Alopexx, Inc.

Alopexx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Alopexx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 27	CI
Alopexx to Present Data on F598, a Novel, Broad-Spectrum Immunotherapeutic at IDWeek 2023	23-10-12	CI
Alopexx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Alopexx, Inc. has filed an IPO in the amount of $18.328125 million.	22-03-04	CI

Alopexx Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). The Company's immune therapeutics target the conserved microbial surface polysaccharide poly N-acetyl glucosamine (PNAG). The Company's vaccine candidate, Vaccine AV0328, is a synthetic PNAG vaccine. It induces antibodies that are capable of killing a wide range of PNAG-expressing pathogens. AV0328 be developed as a complement to Streptococcus pneumonia vaccines (Prevnar, Pneumovax, and Vaxneuvance). AV0328 could protect against many of approximately 80 serotypes. Its Monoclonal antibody F598 is a human monoclonal antibody. It will not replace antibiotics but will instead complement and augment their efficacy and by doing so reduce the development of antibiotic-resistant organisms.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research

Alopexx, Inc.

Equities

ALPX

US02052J1016

Biotechnology & Medical Research

Alopexx, Inc. has filed an IPO in the amount of $18.328125 million.

Latest news about Alopexx, Inc.

Chart Alopexx, Inc.

Company Profile

Sector Other Biotechnology & Medical Research